Indian J Pharm Close
 

Figure 1: Treatment scheme of the 101 patients in this study. AML, acute myeloid leukemia; Allo-HSCT, allogeneic hematopoietic stem cell transplantation; IND1, initial standard anthracycline-plus-cytarabine induction chemotherapy; CR, complete remission; PR, Partial remission; NR, Non-remission; 1: HDAC (high-dose cytarabine); 2: IDAC+M/IDA/VP16/THP (intermediate-dose cytarabine plus mitoxantrone/idarubicin/etoposide/pirarubicin); 3: FLAG (fludarabine, cytarabine, and G-CSF); 4: DA/IA (daunorubicin plus cytarabine/idarubicin plus cytarabine); 5: MA/HA (mitoxantrone plus cytarabine/homoharringtonine plus cytarabine); 6: HD-CAG (high-dose cytarabine and aclarubicin in combination with G-SCF regimen)

Figure 1: Treatment scheme of the 101 patients in this study. AML, acute myeloid leukemia; Allo-HSCT, allogeneic hematopoietic stem cell transplantation; IND1, initial standard anthracycline-plus-cytarabine induction chemotherapy; CR, complete remission; PR, Partial remission; NR, Non-remission; 1: HDAC (high-dose cytarabine); 2: IDAC+M/IDA/VP16/THP (intermediate-dose cytarabine plus mitoxantrone/idarubicin/etoposide/pirarubicin); 3: FLAG (fludarabine, cytarabine, and G-CSF); 4: DA/IA (daunorubicin plus cytarabine/idarubicin plus cytarabine); 5: MA/HA (mitoxantrone plus cytarabine/homoharringtonine plus cytarabine); 6: HD-CAG (high-dose cytarabine and aclarubicin in combination with G-SCF regimen)